MIM
NKTR icon

MetLife Investment Management’s Nektar Therapeutics NKTR Stock Holding History

MetLife Investment Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,033
Closed -$20.7K – 2895
2025
Q1 		$20.7K Sell
2,033
-5,067
-71% -$66.2K ﹤0.01% 2747
2024
Q4 		$99.1K Hold
7,100
– – ﹤0.01% 2628
2024
Q3 		$138K Buy
7,100
+4,000
+129% +$76.2K ﹤0.01% 2473
2024
Q2 		$57.7K Buy
+3,100
New +$65.3K ﹤0.01% 2737
2023
Q2 		– Sell
-4,057
Closed -$42.8K – 2971
2023
Q1 		$42.8K Sell
4,057
-2,279
-36% -$68.9K ﹤0.01% 2728
2022
Q4 		$215K Hold
6,336
– – ﹤0.01% 2206
2022
Q3 		$304K Hold
6,336
– – ﹤0.01% 2011
2022
Q2 		$361K Buy
6,336
+6,097
+2,551% +$385K ﹤0.01% 1885
2022
Q1 		$19.4K Buy
+239
New +$35.4K ﹤0.01% 2710
2021
Q4 		– Sell
-5,887
Closed -$1.59M – 2534
2021
Q3 		$1.59M Sell
5,887
-186
-3% -$44.7K 0.01% 946
2021
Q2 		$1.56M Sell
6,073
-201
-3% -$55.6K 0.01% 964
2021
Q1 		$1.88M Sell
6,274
-271
-4% -$84.3K 0.02% 891
2020
Q4 		$1.67M Sell
6,545
-283
-4% -$73.1K 0.02% 914
2020
Q3 		$1.7M Sell
6,828
-219
-3% -$68.9K 0.02% 788
2020
Q2 		$2.45M Buy
7,047
+315
+5% +$98.3K 0.03% 632
2020
Q1 		$1.8M Hold
6,732
– – 0.02% 653
2019
Q4 		$2.18M Buy
6,732
+3,552
+112% +$1.03M 0.02% 775
2019
Q3 		$869K Sell
3,180
-23
-0.7% -$8.44K 0.01% 1139
2019
Q2 		$1.71M Sell
3,203
-95
-3% -$47.6K 0.02% 880
2019
Q1 		$1.66M Hold
3,298
– – 0.02% 888
2018
Q4 		$1.63M Sell
3,298
-45
-1% -$27.2K 0.02% 841
2018
Q3 		$3.06M Buy
3,343
+181
+6% +$154K 0.03% 657
2018
Q2 		$2.32M Sell
3,162
-4,530
-59% -$5.22M 0.03% 742
2018
Q1 		$12.3M Buy
7,692
+3,228
+72% +$4.16M 0.14% 132
2017
Q4 		$4M Buy
+4,464
New +$2.64M 0.05% 469

Other funds holding NKTR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MetLife Investment Management's NKTR Position: Q2 2025 in Review

MetLife Investment Management sold out of Nektar Therapeutics (NKTR) in Q2 2025, closing a stake of 2,033 shares — an estimated $20.7K sold.

MetLife Investment Management first reported a position in NKTR in Q4 2017 and held it in 25 quarters. The position peaked at $12.3M in Q1 2018. 109 funds tracked by Wall St. Rank hold NKTR as of Q2 2025.

  • MetLife Investment Management reported no remaining Nektar Therapeutics position as of Q2 2025 after selling out during the quarter.
  • MetLife Investment Management sold 2,033 Nektar Therapeutics shares in Q2 2025, an estimated $20.7K.
  • MetLife Investment Management first reported a position in Nektar Therapeutics in Q4 2017 and held it in 25 quarters.
  • MetLife Investment Management's Nektar Therapeutics position peaked at $12.3M in Q1 2018.
  • 109 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2025.

Based on MetLife Investment Management's 13F filing for Q2 2025, filed 13 Aug 2025.